Nanobiotix is a late-stage clinical biotechnology company focused on the discovery, development, manufacture, and commercialization of nanotherapeutics for cancer treatment. Its lead product, NBTXR3, is a radioenhancer designed to increase the effectiveness of radiotherapy in solid tumors while minimizing damage to surrounding healthy tissues. The company engages in global collaborations, including a licensing agreement with Janssen Pharmaceutica NV, to co-develop and commercialize its therapies, primarily targeting cancers of the head, neck, and lungs.